IP Library Granted Patent US 10,696,684
Granted Patent B2
US 10,696,684 · App. 16/690,052 · Granted Jun 30, 2020

Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone

Inventors: Robert Chapman (Downingtown, PA); Lonn S. Rider (Foster, RI); Qi Hong (Sharon, MA); Donald Kyle (Yardley, PA); Robert Kupper (East Greenwich, RI)
Assignees: PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P; RHODES TECHNOLOGIES
C07D489/08A61K9/14A61K9/20A61K9/2095A61K9/48A61K9/4833A61K31/485C07D489/02C07D489/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,696,684
App. No.
16/690,052
Granted
Jun 30, 2020
Kind
B2
Abstract

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

Claims (17)

1. An oxycodone free base composition comprising oxycodone free base and 8α,14-dihydroxy-7,8-dihydrocodeinone, wherein following reacting the oxycodone free base composition with hydrochloric acid to form an oxycodone hydrochloride composition under reaction conditions capable of converting the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone, the amount of 14-hydroxycodeinone that is present in the oxycodone hydrochloride composition is less than 100 ppm.

2. The oxycodone free base composition of claim 1 , wherein the amount of 14-hydroxycodeinone that forms upon conversion of the oxycodone free base to the oxycodone hydrochloride is less than 25 ppm.

3. The oxycodone free base composition of claim 1 , wherein the amount of 14-hydroxycodeinone that forms upon conversion of the oxycodone free base to the oxycodone hydrochloride is less than 10 ppm.

4. An oxycodone acid addition salt composition formed by reacting an oxycodone free base composition of claim 1 with an acid addition salt.

5. The oxycodone acid addition salt of claim 4 , wherein the acid addition salt is hydrochloric acid.

6. The oxycodone acid addition salt of claim 4 , wherein the acid addition salt is sulfuric acid.

7. An oxycodone acid addition salt composition formed by reacting an oxycodone free base composition of claim 2 with an acid addition salt.

8. The oxycodone acid addition salt of claim 7 , wherein the acid addition salt is hydrochloric acid.

9. The oxycodone acid addition salt of claim 7 , wherein the acid addition salt is sulfuric acid.

10. The oxycodone free base composition of claim 1 , wherein following reacting the oxycodone free base composition with hydrochloric acid, the ratio of 8α,14-dihydroxy-7,8-dihydrocodeinone to the oxycodone hydrochloride is 0.04% or less as measured by HPLC.

11. An oxycodone free base composition comprising oxycodone free base and 8α,14-dihydroxy-7,8-dihydrocodeinone, wherein following reacting the oxycodone free base composition with hydrochloric acid to form an oxycodone hydrochloride composition under reaction conditions capable of converting the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone, the ratio of 8α,14-dihydroxy-7,8-dihydrocodeinone to oxycodone hydrochloride is 0.04% or less as measured by HPLC.

12. The oxycodone free base composition of claim 11 , which further comprises 14-hydroxycodeinone, and wherein the amount of 14-hydroxycodeinone is less than 25 ppm.

13. An oxycodone acid addition salt composition formed by reacting an oxycodone free base composition of claim 11 with an acid addition salt.

14. The oxycodone acid addition salt of claim 13 , wherein the acid addition salt is hydrochloric acid.

15. The oxycodone acid addition salt of claim 13 , wherein the acid addition salt is sulfuric acid.

16. An oxycodone free base composition comprising oxycodone free base and 8α,14-dihydroxy-7,8-dihydrocodeinone, wherein the ratio of 8α,14-dihydroxy-7,8-dihydrocodeinone to oxycodone is 0.04% or less as measured by HPLC.

17. The oxycodone free base composition of claim 16 , which further comprises 14-hydroxycodeinone, and wherein the amount of 14-hydroxycodeinone is less than 25 ppm.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2020
From: CHAPMAN, ROBERT; RIDER, LONN S; HONG, QI; KYLE, DONALD
To: EURO-CELTIQUE S.A.
Reel/Frame 052369/0946 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2020
From: EURO-CELTIQUE S.A.
To: PURDUE PHARMA L.P.
Reel/Frame 052369/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2020
From: PURDUE PHARMA L.P.
To: PURDUE PHARMA L.P.; THE P.F. LABORATORIES, INC.; PURDUE PHARMACEUTICALS L.P.; RHODES TECHNOLOGIES
Reel/Frame 052369/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2020
From: THE P.F. LABORATORIES, INC.; PURDUE PHARMA TECHNOLOGIES, INC.
To: PURDUE PHARMA L.P.
Reel/Frame 052370/0001 →
Continuity (17)
Continuation 16557937 · Aug 30, 2019
Continuation 16262683 · Jan 30, 2019
Continuation 15721167 · Sep 29, 2017
Continuation 15058420 · Mar 2, 2016
Continuation 14725210 · May 29, 2015
Continuation 13366755 · Feb 6, 2012
Continuation 12893681 · Sep 29, 2010
Continuation 12380800 · Mar 4, 2009
Continuation 11653529 · Jan 16, 2007
Continuation 11391897 · Mar 29, 2006
Continuation 11093626 · Mar 30, 2005
Provisional Application 60651778 · Feb 10, 2005
Provisional Application 60648625 · Jan 31, 2005
Provisional Application 60620072 · Oct 18, 2004
Provisional Application 60601534 · Aug 13, 2004
Provisional Application 60557492 · Mar 30, 2004
Related Publication 20200087316A1 · Mar 19, 2020